DPP4 and type 2 diabetes mellitus: In support of the above, in a Taiwanese national cohort, (47,405 patients with T2D who received an SGLT2i compared with 47,405 individuals matched for propensity score who received dipeptidyl peptidase 4 inhibitors), the use of SGLT2i in T2D was associated with a lower risk of gout incidence than the use of DPP4 inhibitors [75].